2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension

TSOC pulmonary hypertension committee

研究成果: Article

摘要

Pulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH. 4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.

原文English
期刊Journal of the Formosan Medical Association
DOIs
出版狀態Published - 2019 一月 1

指紋

Cardiology
Taiwan
Pulmonary Hypertension
Guidelines
Connective Tissue Diseases
Vascular Resistance
Echocardiography
Heart Diseases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

引用此文

@article{c7c2587aa90f4bffa5bacefdfd88b670,
title = "2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH. 4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.",
author = "{TSOC pulmonary hypertension committee} and Huang, {Wei Chun} and Hsu, {Chih Hsin} and Chin-Hsin Hsu and Ho, {Wan Jing} and Chu, {Chun Yuan} and Chang, {Chih Ping} and Chiu, {Yu Wei} and Wu, {Chun Hsien} and Chang, {Wei Ting} and Lin Lin and Lin, {Shoa Lin} and Cheng, {Chin Chang} and Wu, {Yih Jer} and Wu, {Shu Hao} and Hsieh, {Tsu Yi} and Hsu, {Hsao Hsun} and Morgan Fu and Dai, {Zen Kong} and Kuo, {Ping Hung} and Hwang, {Juey Jen} and Cheng, {Shu Meng}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jfma.2018.12.009",
language = "English",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Excerpta Medica Asia Ltd.",

}

TY - JOUR

T1 - 2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension

AU - TSOC pulmonary hypertension committee

AU - Huang, Wei Chun

AU - Hsu, Chih Hsin

AU - Hsu, Chin-Hsin

AU - Ho, Wan Jing

AU - Chu, Chun Yuan

AU - Chang, Chih Ping

AU - Chiu, Yu Wei

AU - Wu, Chun Hsien

AU - Chang, Wei Ting

AU - Lin, Lin

AU - Lin, Shoa Lin

AU - Cheng, Chin Chang

AU - Wu, Yih Jer

AU - Wu, Shu Hao

AU - Hsieh, Tsu Yi

AU - Hsu, Hsao Hsun

AU - Fu, Morgan

AU - Dai, Zen Kong

AU - Kuo, Ping Hung

AU - Hwang, Juey Jen

AU - Cheng, Shu Meng

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH. 4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.

AB - Pulmonary arterial hypertension (PAH) is characterized as a progressive and sustained increase in pulmonary vascular resistance, which may induce right ventricular failure. In 2014, the Working Group on Pulmonary Hypertension of the Taiwan Society of Cardiology (TSOC) conducted a review of data and developed a guideline for the management of PAH. 4 In recent years, several advancements in diagnosis and treatment of PAH has occurred. Therefore, the Working Group on Pulmonary Hypertension of TSOC decided to come up with a focused update that addresses clinically important advances in PAH diagnosis and treatment. This 2018 focused update deals with: (1) the role of echocardiography in PAH; (2) new diagnostic algorithm for the evaluation of PAH; (3) comprehensive prognostic evaluation and risk assessment; (4) treatment goals and follow-up strategy; (5) updated PAH targeted therapy; (6) combination therapy and goal-orientated therapy; (7) updated treatment for PAH associated with congenital heart disease; (8) updated treatment for PAH associated with connective tissue disease; and (9) updated treatment for chronic thromboembolic pulmonary hypertension.

UR - http://www.scopus.com/inward/record.url?scp=85063333446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063333446&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2018.12.009

DO - 10.1016/j.jfma.2018.12.009

M3 - Article

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

ER -